Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

Biologic or biosimilar: what are prescribers thinking?

Biologic or biosimilar: what are prescribers thinking? Herceptin has been around for 12–13 years. Biosimilars are new drugs; we don’t have the same data for them.

Mylan gets first biosimilar Herceptin OK from FDA

Mylan gets first biosimilar Herceptin OK from FDA Mylan has become the first pharma company to win US approval for a biosimilar of Roche’s big-selling cancer antibody Herceptin. ... have suggested it will start making revenues from the drug in 2019 – the year in which Roche’s US patent on

First Herceptin biosimilar cleared in Europe

First Herceptin biosimilar cleared in Europe means it can now threaten the CHF 2.1bn in European sales achieved by Herceptin last year. ... Roche is claiming patent protection for Herceptin in the US out to 2019, but its EU patents expired in 2014.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics